RedHill Biopharma Ltd's (Nasdaq: RDHL) Guy Goldberg talks to Proactive London about their operations, which include working towards a remedy for Covid-19 with Opaganib.
Goldberg describes the drug as 'one of most advantaged, novel investigational Covid-19 drugs'. Opaganib is orally-taken, which targets a host cell component and is unaffected by viral mutation.
Goldberg explains why the drug is unique with its 'mechanism for action', first being that it is anti-viral and secondly, that it is anti-inflammatory'.
The medicine is already available in Israel on a 'compassionate' use basis, which has proved successful for five patients who had 'moderate to severe' Covid-19 symptoms.